Physician profile
Michael Sarosdy
NPI 1649273442
$10,837.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $3,368 · 2021: $7,116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $9,336.51 | 2020-2021 | |
| Antares Pharma, INC. | $355.87 | 2019-2021 | |
| Pfizer INC. | $314.28 | 2019-2021 | |
| Astellas Pharma US INC | $189.98 | 2020-2021 | |
| Janssen Biotech, INC. | $188.83 | 2020-2021 | |
| Myovant Sciences INC. | $160.04 | 2021 | |
| Neotract INC. | $122.79 | 2019 | |
| Acerus Pharmaceuticals Corporation | $65.80 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $32.33 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $21.75 | 2020 | |
| 180 Medical, INC. | $19.72 | 2021 | |
| Endo Pharmaceuticals INC. | $15.19 | 2021 | |
| Abbvie INC. | $14.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sarosdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.